Guideline for blood grouping and red cell antibody testing in pregnancy

Transfusion Medicine

Volumn 26, Issue 4, 2016, Pages 246-263

  White, J ^a   Qureshi, H ^b   Massey, E ^c   Needs, M ^d   Byrne, G ^b   Daniels, G ^d   Allard, S ^e  

^a United Kingdom National External Quality Assessment Scheme for General Haematology (UK NEQAS (H))   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^c UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^d NHS BLOOD AND TRANSPLANT   (United Kingdom)

^e BARTS HEALTH NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROCYTE ANTIBODY; RHESUS D ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; BIRTH; BLOOD GROUP KELL SYSTEM; BLOOD GROUP TYPING; CLINICAL PROTOCOL; COOMBS TEST; FEMALE; FETUS; GENOTYPE; HUMAN; IMMUNOASSAY; LABORATORY TEST; MEASUREMENT; PREGNANCY; PRENATAL PERIOD; TIME; UMBILICAL CORD;

EID: 84963825513     PISSN: 09587578     EISSN: 13653148     Source Type: Journal    
DOI: 10.1111/tme.12299     Document Type: Article

References (64)

1. Ahaded, A., Brossard, Y., Debbia, M. & Lambin, P. (2000) Quantitative determination of anti-K [KEL1] IgG and IgG subclasses in the serum of severely alloimmunized pregnant women by ELISA. Transfusion, 40, 1239–1245.
2. b using intrauterine transfusions with serial maternal blood donations: a case report and a review of the literature. Transfusion, 54, 238–243.
3. Bichler, J., Schondorfer, G., Pabst, G. & Andresen, I. (2003) Pharmacokinetics of anti-D IgG in pregnant RhD-negative women. British Journal of Obstetrics and Gynaecology, 110, 39–45.
4. Bowell, P., Wainscoat, J.S., Peto, T.E.A. & Gunson, H.H. (1982) Maternal anti-D concentrations and outcome in rhesus haemolytic disease of the newborn. British Medical Journal, 285, 327–329.
5. British Committee for Standards in Haematology (BCSH) (2009a): Harris AM, Atterbury CLJ, Chaffe B, Elliott C, Hawkins T, Hennem SJ, Howell C, Jones J, Murray S, New HV, Norfolk D, Pirie L, Russell J, Taylor C. Guideline on the Administration of Blood Components. URL http://www.bcshguidelines.com (Accessed 5/4/15).
6. British Committee for Standards in Haematology (BCSH) (2009b): E Austin, S Bates, M de Silva, D Howarth, A Lubenko, M Rowley, M Scott, E Thomas, J White, M Williams. Guidelines for the Estimation of Fetomaternal Haemorrhage. URL http://www.bcshguidelines.com/documents/BCSH_FMH_bcsh_sept2009.pdf.
7. British Committee for Standards in Haematology (BCSH), Gooch, A., Parker, J., Wray, J. & Qureshi, H. (2007) Guidelines for blood grouping and antibody testing in pregnancy. Transfusion Medicine, 17, 252–262.
8. British Committee for Standards in Haematology (BCSH), Allard, S., Burgess, G. et al. (2012a) Guidelines for validation and qualification, including change control, for hospital transfusion laboratories. Transfusion Medicine, 22, 5–43.
9. British Committee for Standards in Haematology (BCSH), Milkins, C., Berryman, J. et al. (2012b) Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories. Transfusion Medicine, 23, 3–35.
10. British Committee for Standards in Haematology (BCSH), Qureshi, H., Massey, E. et al. (2014) Guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn. Transfusion Medicine, 24, 8–20.
11. Bruce, D.G., Tinegate, H.N., Williams, M., Babb, R. & Wells, A.W. (2013) Antenatal monitoring of anti-D and anti-c: could titre scores determined by column agglutination technology replace continuous flow analyser quantification? Transfusion Medicine, 23, 36–41.
12. Cambic, C.R., Scavone, B.M., McCarthy, R.J., Eisenberg, P., Sanchez, E.M., Sullivan, J.T. & Wong, C.A. (2010) A retrospective study of positive antibody screens at delivery in Rh-negative parturients. Canadian Journal of Anaesthesia, 57, 811–6. Epub 2010 Jul 27.
13. Chilcott, J., Lloyd-Jones, M., Wight, J., Forman, K., Wray, J., Beverley, C. & Tappenden, P. (2003) A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative. Health Technology Assessment, 7, iii–62.
14. Chitty, L.S., Finning, K., Wade, A., Soothill, P., Martin, B., Oxenford, K., Daniels, G. & Massey, E. (2014) Diagnostic accuracy of routine antenatal determination of fetal RHD status across gestation: population based cohort study. BMJ, 349, Article g5243. DOI: 10.1136/bmj.g5243.
15. Clark, D., Greiss, M.A. & Urbaniak, S.J. (1999) A prospective study of routine antenatal enzyme antibody screening demonstrates lack of clinical value in predicting haemolytic disease of the newborn. British Journal of Haematology, 106, 824–826.
16. Clausen, F.B., Christiansen, M., Steffensen, R. et al. (2012) Report of the first nationally implemented clinical routine screening for fetal RHD in D− pregnant women to ascertain the requirement for antenatal RhD prophylaxis. Transfusion, 52, 752–758.
17. Critical Appraisal Skills Programme (CASP) website. http://www.casp-uk.net/#!casp-tools-checklists/c18f8 (accessed 28/03/2016).
18. Daniels, G. (2013) Human Blood Groups (3rd edn). Wiley Blackwell.
19. Daniels, G., Poole, J., de, Silva, M., Callaghan, T., MacLennan, S. & Smith, N. (2002) The clinical significance of blood group antibodies. Transfusion Medicine, 12, 287–295.
20. Daniels, G., Hadley, A. & Green, C.A. (2003) Causes of fetal anemia in haemolytic disease due to anti-K. Transfusion, 43, 115–116.
21. Daniels, G., Finning, K., Martin, P. & Massey, E. (2009) Noninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects. Prenatal Diagnosis, 29, 101–7.
22. Daniels, G., Finning, K. & Martin, P. (2010) Noninvasive fetal blood grouping: present and future. Clinics in Laboratory Medicine, 30, 431–442.
23. Dillon, A., Chaudhari, T., Crispin, P., Shadbolt, B. & Kent, A. (2011) Has anti-D prophylaxis increased the rate of positive direct antiglobulin test results and can the direct antiglobulin test predict need for phototherapy in Rh/ABO incompatibility? Journal of Paediatrics and Child Health, 47, 40–3.
24. Eklund, J., Hermann, M., Kjellman, H. & Pohja, P. (1982) Turnover rate of anti-D IgG injected during pregnancy. British Medical Journal, 284, 854–855.
25. Finning, K., Martin, P., Summers, J. & Daniels, G. (2007) Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell-free fetal DNA in maternal plasma. Transfusion, 47, 2126–2133.
26. Finning, K., Martin, P., Summers, J., Massey, E., Poole, G. & Daniels, G. (2008) Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study. BMJ, 336, 816–8.
27. a and the potential clinical value of Duffy genotyping in pregnancies at risk. Transfusion Medicine, 7, 301–304.
28. Heddle, N.M., Klama, L., Frassetto, R., O'Hoski, P. & Leman, B. (1993) A retrospective study to determine the risk of red cell alloimmunization and transfusion during pregnancy. Transfusion, 33, 217–220.
29. Howard, H., Martlew, V., McFaden, I., Clarke, C., Duguid, J., Bromilow, I. & Eggington, J. (1998) Consequences for fetus and neonate of maternal red cell allo-immunisation. Archives of Disease in Childhood. Fetal and Neonatal Edition, 78, F62–F66.
30. Joy, S.D., Rossi, K.Q., Krugh, D. & O'Shaughnessy, R.W. (2005) Management of pregnancies complicated by anti-E alloimmunization. Obstetrics and Gynecology, 105, 24–8.
31. Koelewijn, J.M., Vrijkotte, T.G., van der, Schoot, C.E., Bonsel, G.J. & de, Haas, M. (2008) Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion, 48, 941–952.
32. Kozlowski, C.L., Lee, D., Shwe, K.H. & Love, E.M. (1995) Quantification of anti-c in haemolytic disease of the newborn. Transfusion Medicine, 5, 37–42.
33. Lee, E. & de, Silva, M. (2004) Unlike anti-c, anti-K in pregnancy is more likely to have been induced by previous transfusion; this can be prevented. Transfusion, 44 (9S), 104A.
34. Li, P., Pang, L.H., Liang, H.F., Chen, H.Y. & Fan, X.J. (2015) Maternal IgG anti-A and anti-B titer levels screening in predicting ABO hemolytic disease of the newborn: a meta-analysis. Fetal and Pediatric Pathology, 34, 341–50.
35. Maayan-Metzger, A., Schwartz, T., Sulkes, J. & Merlob, P. (2001) Maternal anti-D prophylaxis during pregnancy does not cause neonatal haemolysis. Archives of Disease in Child Fetal Neonatal, edition, 84, F60–F62.
36. Maley, M., Babb, R., Chapman, C.E., Fitzgerald, J. & Cavanagh, G. (2001) Identification and quantification of anti-D, -C and -G in alloimmunized pregnant women. Transfusion Medicine, 11, 443–446.
37. McKenna, D.S., Nagaraja, H.N. & O'Shaughnessy, R. (1999) Management of pregnancies complicated by anti-Kell isoimmunisation. Obstetrics and Gynecology, 93, 667–673.
38. Moise, K.J. (2000) Non-anti-D antibodies in red cell alloimmunisation. European Journal of Obstetrics and Gynecology and Reproductive Biology, 92, 75–81.
39. Mollison, P.L., Engelfreit, C.P. & Contreras, M. (1997) No value in immune anti-A or anti-B in predicting HDFN. In: Blood Transfusion in Clinical Medicine (10 edn), p418–24. Blackwell Oxford.
40. Moran, P., Robson, S.C. & Reid, M.M. (2000) Anti-E in pregnancy. British Journal of Obstetrics and Gynecology, 107, 1436–1438.
41. National Institute for Biological Standards and Control (NIBSC) (2010a) ‘Anti-D for assuring operator and test performance NIBSC code: 07/304 Instructions for use (Version 2.0, Dated 21/06/2010). URL http://www.nibsc.org/documents/ifu/07-304.pdf (Accessed on 22/02/16).
42. National Institute for Biological Standards and Control (NIBSC) (2010b) ‘Anti-D (Rho) Antibodies, Human British Standard NIBSC code: 73/515 Instructions for use (Version 7.0, Dated 20/11/15). URL http://www.nibsc.org/documents/ifu/73-515.pdf (Accessed on 22/02/16).
43. National Institute for Biological Standards and Control (NIBSC) (2010c) Anti-c Serum, Human NIBSC code: 84/628 Instructions for use (Version 8.0, Dated 19/11/2015). URL http://www.nibsc.org/documents/ifu/84-628.pdf (Accessed on 22/02/16).
44. National Institute for Health and Care Excellence (NICE), Health Technology Appraisal Guidance 156. (2008) Routine antenatal anti-D prophylaxis for women who are rhesus D negative Review of NICE technology appraisal guidance 41 http://www.nice.org.uk/guidance/ta156/resources/guidance-routine-antenatal-antid-prophylaxis-for-mothers-who-are-rhesus-d-negative-pdf (Accessed on 30/10/2014).
45. National Institute for Health and Care Excellence (NICE), Clinical Guidance 98 (2010) Jaundice in Newborn Babies. URL http://www.nice.org.uk/guidance/cg98/resources/guidance-neonatal-jaundice-pdf (Accessed on 30/10/2014).
46. National Institute for Health and Care Excellence (NICE), Clinical Guidance 62, 2008 Antenatal Care. URL http://www.nice.org.uk/guidance/cg62/resources/guidance-antenatal-care-pdf (Accessed 30/10/2014).
47. New, H.V., Harrison, C.N., Rodeck, C.H., de, Silva, M. & Cohen, H. (2001) Antenatal antibody screening. Lancet, 357, 1295.
48. NHS Blood and Transplant (2015): SPN214/3. The Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion. URL http://hospital.blood.co.uk/media/27446/spn2143-the-clinical-significance-of-blood-group-alloantibodies-and-the-supply-of-blood-for-transfusion.pdf (Accessed 5/5/2015)
49. Nicolaides, K.H. & Rodeck, C.H. (1992) Maternal serum anti-D antibody concentration and assessment of rhesus isoimmunisation. British Medical Journal, 304, 1155–1156.
50. Nordvall, M., Dziegiel, M., Hegaard, H.K., Bidstrup, M., Jonsbo, F., Christensen, B. & Hedegaard, M. (2009) Red blood cell antibodies in pregnancy and their clinical consequences: synergistic effects of multiple specificities. Transfusion, 49, 2070–5.
51. Pal, M. & Williams, B. (2015) Prevalence of maternal red cell alloimmunisation: a population study from Queensland, Australia. Pathology, 47, 151–5.
52. Pate, L.L., Myers, J.C., Palma, J.P. et al. (2013) Anti-Ge3 causes late-onset hemolytic disease of the newborn: the fourth case in three Hispanic families. Transfusion, 53, 2152–2157.
53. Rothenberg, J.M., Weirermiller, B., Dirig, K., Hurd, W.W., Schilder, J. & Golichowski, A. (1999) Is a third-trimester antibody screen for Rh+ women necessary? American Journal of Managed Care, 5, 1145–50.
54. Royal College of Obstetricians and Gynaecologists (RCOG) The Management of Women with Red Cell Antibodies During Pregnancy. Green-Top Guidelines no. 65 May 2014. URL https://www.rcog.org.uk/globalassets/documents/guidelines/rbc_gtg65.pdf (Accessed on 30/10/2014).
55. Scheier, M., Hernandez-Andrade, E., Carmo, A., Dezerega, V. & Nicolaides, K.H. (2004) Prediction of fetal anemia in rhesus disease by measurement of fetal middle cerebral artery peak systolic velocity. Ultrasound in Obstetrics and Gynecology, 23, 432–436.
56. Scottish National Blood Transfusion Service (SNBTS) (2013): Pregnant Women with Red Cell Antibodies: Scottish National Clinical Guidance. Version 2 July 2013. URL http://www.scotblood.co.uk/media/101700/pregnant_women_with_red_cell_antibodies_scottish_national_clinical_guidance_august13.pdf (Accessed 05/05/15)
57. Serious Hazards of Transfusion (SHOT UK 2012), 2011 Annual SHOT report. URL www.shot-uk.org (Accessed on 30/10/14).
58. Smith, G., Knott, P., Rissik, J., de la, Fuente, J. & Win, N. (1998) Anti-U and haemolytic disease of the fetus and newborn. British Journal of Obstetrics and Gynaecology, 105, 1318–1321.
59. Smith, H.M., Shirey, R.S., Thoman, S.K. & Jackson, J.B. (2013) Prevalence of clinically significant red blood cell alloantibodies in pregnant women at a large tertiary-care facility. Immunohematology, 29, 127–30.
60. Soothill, P., Finning, K., Latham, T., Wreford-Bush, T., Ford, J. & Daniels, G. (2015) Use of cffDNA to avoid administration of anti-D to pregnant women when the fetus is RhD-negative: implementation in the NHS. British Journal of Obstetrics & Gynaecology. 122(12):1682–1686.
61. The International Blood Group Reference Laboratory (IBGRL). URL: http://ibgrl.blood.co.uk/ReferenceServices/ReferenceServhome2015.htm (Accessed on 18/01/16).
62. Thompson, S., Eggington, J., Dodd, A., Qureshi, R. & Turner, E. (2003) Late developing red cell antibodies in pregnancy. Transfusion Medicine, 13 (supp), 8–9.
63. Vaughan, J.I., Manning, M., Warwick, R.M., Letsky, E.A., Murray, N.A. & Roberts, I.A.G. (1998) Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. New England Journal of Medicine, 338, 798–803.
64. Yasuda, H., Ohto, H., Nollet, K.E., Kawabata, K., Saito, S., Yagi, Y., Yutaka, N. & Ishida, A. (2014) Hemolytic disease of the fetus and newborn with late-onset anemia due to anti-M: a case report and review of the Japanese literature. Transfusion Medicine Reviews. 28(1):1–6.